Our proprietary miRNA technology detects cancer at its earliest, most treatable stages. With minimally invasive test and accurate insights, our tests enable patients to act sooner.
A pioneering blood test for the early detection of gastric (stomach) cancer.
A minimally invasive blood test designed to identify lung cancer at an early stage.
We leverage advanced Next-Generation Sequencing (NGS) technology to empower patients in personalised cancer treatment selection.
A Targeted 58-Gene Profiling Test
A Comprehensive 1021-Gene Profiling Test
Tested and proven testing solutions.
Multiplex RT-PCR Test for SARS-CoV-2
RT-PCR Kit for SARS-CoV-2 & Flu A/B
RNA Swab & Saliva Kits
Molecular & COVID-19 RNA Extraction
Cryomics offers unmatched biobanking solutions, from secure storage to consultancy.
Partnering Discovery
Early detection of HCC and Multi-Cancer Screening Test (MCST) Development
EarLy DEtection of HCC
Multi-Cancer Screening Test (MCST) Development
At Mirxes, we innovate with purpose, impact the world, and invest in your growth.
Be part of the team delivering world-leading multi-cancer early detection.
An exclusive talent development programme developed by Enterprise Singapore.
MiRXES’ cancer screening solutions leverage advanced RNA-based technology to detect cancer at its earliest, most treatable stages. With accurate and minimally invasive insights, our tests empower patients and clinicians to act sooner.
Lorem ipsum dolor sit amet, consectetur adipiscing elit.
Please fill out the form or reach us anytime in the contact details below.
